Biotech company and market leader in making diagnostics psychedelics Nova Mentis Life Science Corp. (CNSX: NOVA) (OTCQB: NMLSF) announced promising results of its ongoing study of using psilocybin on anxiety behaviors linked to Autism Spectrum Disorder (ASD).
Chief Executive of Nova Mentis, Will Rascan, says they have discovered early signs of a rescue effect in using psilocybin for ASD patients.
“The early results from this study are very encouraging and further validate our team’s efforts to establish the therapeutic potential of psilocybin for ASD patients,” said Rascan.
The CEO however acknowledged the study is still under progress and there is need to confirm the results before making any major conclusions. To further cement these findings, Nova is engaging established scientific research facilities to analyze and verify its data and information.
The main aim of the study is to find out the efficacy rate of psilocybin in treating autism spectrum disorder (ASD), to find out the reaction of an ASD patient to psychedelic drug and to establish the exact therapeutic amount of psilocybin to be used in an upcoming human trial.